Amylgen
Entity

  • Amylgen

    Created in 2009
  • BETA

    Probably non active (C)
    Several signals show that this company is not active anymore

  • Social networks

    217 757

  • Activities

    healthtech deeptech biotech

  • Technologies

    Data Analytics

  • Entity types

    Startup

  • Location

    34980 Montferrier-sur-Lez, France

    Montferrier-sur-Lez

    France

  • Employees

    Scale: 2-10

    Estimated: 1

  • SIREN

    515241065

  • Engaged corporates

    1
    0 0

  • Added in Motherbase

    5 years, 7 months ago
Description
  • Value proposition

    Amylgen is a CRO proposing innovative in vivo models of ageing, psychiatric and neurodegenerative pathologies for the development of new medicines or nutraceuticals.

    Amylgen is at your service to provide quick POC for your product as a food supplement for brain health and helps you to substantiate the efficacy of your product by preclinical studies in rodent models

    Amylgen brings you preclinical scientific data for your product on
    Brain aging preservation
    Memory enhancement
    Antidepressant /anti anxiety effect
    Protection against Alzheimer’s disease

    Amylgen has access to regulatory and clinical partners to aid in the preparation of health claims for EFSA or FDA and the commercialization of your product

    in vivo pharmacology, Behavioral pharmacology, neurodegenerative diseases, and Central nervous system

  • Original language

    Amylgen is a CRO proposing innovative in vivo models of ageing, psychiatric and neurodegenerative pathologies for the development of new medicines or nutraceuticals.

    Amylgen is at your service to provide quick POC for your product as a food supplement for brain health and helps you to substantiate the efficacy of your product by preclinical studies in rodent models

    Amylgen brings you preclinical scientific data for your product on
    Brain aging preservation
    Memory enhancement
    Antidepressant /anti anxiety effect
    Protection against Alzheimer’s disease

    Amylgen has access to regulatory and clinical partners to aid in the preparation of health claims for EFSA or FDA and the commercialization of your product

Corporate interactions BETA
Corporate TypeTweets Articles
La Tribune
La Tribune
Media, Newspapers
La Tribune
Media, Newspapers 		Other

11 Jun 2015


Similar entities
Last news
Show all articles
Social network dynamics